Because mTOR dysregulation occurs in DM, there are ongoing biochemistry efforts to target mTOR signaling for protecting against diabetic-associated complication(s) [20,21] Systemic administration of rapamycin ameliorates diabetes-induced renal dysfunction, a hypothesis to be examined in the current study. The gene discussed is MTOR; the disease is diabetes mellitus.